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African sleeping sickness is a fatal parasitic disease, and all drugs currently in use for treatment have strong
liabilities. It is essential to find new, effective, and less toxic drugs, ideally with oral application, to control the
disease. In this study, the aromatic diamidine DB75 (furamidine) and two aza analogs, DB820 and DB829
(CPD-0801), as well as their methoxyamidine prodrugs and amidoxime metabolites, were evaluated against
African trypanosomes. The active parent diamidines showed similar in vitro profiles against different Trypano-
soma brucei strains, melarsoprol- and pentamidine-resistant lines, and a P2 transporter knockout strain
(AT1KO), with DB75 as the most trypanocidal molecule. In the T. b. rhodesiense strain STIB900 acute mouse
model, the aza analogs DB820 and DB829 demonstrated activities superior to that of DB75. The aza prodrugs
DB844 and DB868, as well as two metabolites of DB844, were orally more potent in the T. b. brucei strain
GVR35 mouse central nervous system (CNS) model than DB289 (pafuramidine maleate). Unexpectedly, the
parent diamidine DB829 showed high activity in the mouse CNS model by the intraperitoneal route. In
conclusion, DB868 with oral and DB829 with parenteral application are potential candidates for further
development of a second-stage African sleeping sickness drug.
Sleeping sickness, also called human African trypanosomia-
sis (HAT), is a vector-borne parasitic disease caused by
Trypanosoma brucei subspecies, which are unicellular flagel-
lated protozoans. Depending on the subspecies, there are two
different forms of the disease which show different clinical
features. West African sleeping sickness, a more chronic dis-
ease caused by T. b. gambiense, is prevalent in West and Cen-
tral Africa. East African sleeping sickness, a more acute and
virulent disease caused by T. b. rhodesiense, is endemic in East
and Southern Africa (7). The disease is transmitted by the bite
of an infected tsetse fly. Tsetse flies and, consequently, the
disease are found in remote rural areas of sub-Saharan Africa.
The number of sleeping sickness cases decreased in recent
years to 12,000 reported cases (28) and 50,000 to 70,000
estimated cases (35) due to improved HAT control.
There are two stages of the disease. In the first stage, the
parasites reside and proliferate in the hemolymphatic system.
In the second, encephalitic stage, the parasites cross the blood-
brain barrier (BBB) and infect the central nervous system
(CNS) and the cerebrospinal fluid. The second stage is difficult
to treat, as the BBB is a barrier for most drugs, preventing
trypanocidal levels of those agents in the CNS and cerebrospi-
nal fluid. If untreated, the disease is invariably fatal. HAT
exclusively affects the world’s poorest populations, making
drug development against this tropical disease economically
unattractive for pharmaceutical industries (7, 30, 33). As a
consequence, HAT has become one of the most neglected
tropical diseases. The drugs currently in use against HAT are
unsatisfactory, especially those for the second stage. All drugs
suffer from poor oral bioavailability and must be administered
parenterally, causing compliance problems in rural areas where
health systems are poorly developed or nonexistent. Additionally,
the treatment schedule is long and laborious and the adverse
events severe or even lethal. Up to 5% of the patients treated with
the second-stage drug melarsoprol die of a reactive encephalop-
athy (18). Drug resistance is also of growing concern and, espe-
cially for the encephalitic stage, there are no appropriate treat-
ment options available after treatment failures. Consequently,
new drugs are desperately needed to combat this disease.
One of the drugs currently in use for the hemolymphatic stage
is the aromatic diamidine pentamidine. It has a broad spectrum of
antiparasitic activities and is also used clinically against antimony-
resistant leishmaniasis and against Pneumocystis jiroveci infection,
mostly in AIDS patients (29). This old drug has been used since
the early 1940s for the treatment of first-stage T. b. gambiense
HAT (13). The use of pentamidine is partially restricted due to its
lack of oral bioavailability and its toxicity.
The aim of this work was to develop novel aromatic diami-
dines that are effective for first-stage disease (oral administra-
tion) or are effective for second-stage HAT (oral or parenteral
administration). A leading structure is DB75 [furamidine; 2,5-
bis(4-aminophenyl)-furan], which has a broad spectrum of an-
tiparasitic activity covering P. jiroveci, Leishmania spp., Giardia
intestinalis, Plasmodium falciparum, and Trypanosoma spp. The
diphenylfuran diamidines represent an important class of
DNA minor groove binders (32, 34). The selective and rapid
uptake leads to high drug accumulation in the parasite (21, 22).
However, like most of the aromatic diamidines, furamidine
and its analogs have low oral bioavailability due to their pos-
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itively charged amidine groups and are therefore orally not
effective. To improve the oral bioavailability, prodrugs were
synthesized. After oral absorption through the gastrointestinal
barrier, they are metabolized to their active trypanocidal parent
drugs. This approach was successful for DB75 and its prodrug
DB289 [pafuramidine maleate; 2,5-bis(4-amidinophenyl)-furan-
bis-O-methlylamidoxime], which became the first oral drug for
sleeping sickness to enter clinical trials for the first stage. In a
pivotal phase III trial, 273 patients were enrolled between August
2005 and March 2007. In October 2008, an additional phase I
study of healthy volunteers was initiated to complete the safety
assessment for registration of DB289 for sleeping sickness and
Pneumocystis jiroveci. In the extended phase I trial, more severe
liver toxicity and delayed renal insufficiency were observed in a
number of participants and, as a consequence, the DB289 devel-
opment program was discontinued (25). The mechanism of tox-
icity of DB289, particularly the delayed renal toxicity, is currently
being further studied in animal models.
Many analogs of DB75/DB289 have been synthesized and
tested in vitro and in vivo to find a new clinical candidate,
especially for second-stage disease. Several of those analogs
were effective in our stringent T. b. rhodesiense strain STIB900
acute mouse model (2). However, only a very few have shown
good activity in the T. b. brucei strain GVR35 mouse CNS
model. DB289 resulted in cures of 60% of GVR35-infected
mice, but it was not effective in the vervet monkey CNS model
(24). Though it was able to cure one-third of monkeys with an
early CNS infection when treatment was initiated on day 14
postinfection, it was not curative when treatment was delayed
to day 28 postinfection, a time point when brain infection is
well established (24). DB289 can therefore not be considered
a clinical candidate for second-stage disease, but its aza ana-
logs have more potential and were evaluated in this study.
MATERIALS AND METHODS
Materials. Pentamidine isethionate and diminazene aceturate were purchased
from Sigma-Aldrich; melarsoprol (Aventis) was provided by WHO; and DB75
and DB289 were provided by Immtech Pharmaceuticals. DB820, DB844, DB829,
and DB868 were provided by David Boykin; their synthesis has been reported
(16). The intermediates DB290, DB775, DB821, DB840, DB1058, DB1284, and
DB1679 were also provided by David Boykin. Synthesis has been reported for
DB290 (10), DB775 (1), DB821 (16), DB840 (16), and DB1058 and DB1284
(15). The synthesis of DB1679 has not been published yet.
Preparation of compounds. Compounds were dissolved in 100% dimethyl sul-
foxide (DMSO) and finally diluted in culture medium prior to the assay. The DMSO
concentration never exceeded 1% in the in vitro assays. For in vivo experiments, the
compounds were dissolved in DMSO and further diluted with distilled H2O to a final
DMSO concentration of 10% prior to administration to animals.
Parasites. (i) T. b. rhodesiense. T. b. rhodesiense strain STIB900 is a derivative
of strain STIB704. The strain was isolated from a patient in Ifakara, Tanzania, in
1982. STIB900 is used for routine in vitro screening and for the acute mouse
model which mimics the first stage of HAT (31). STIB900mel and STIB900pent
are melarsoprol- and pentamidine-resistant populations, respectively. When
tested along with these drug-resistant lines, STIB900 was named STIB900wt.
These resistant lines were generated by growing STIB900 in increasing subcu-
rative drug concentrations (8).
(ii) T. b. gambiense. The T. b. gambiense strains used include STIB930, a
derivate of strain TH1/78E(031), which was isolated from a patient in Côte
d’Ivoire in 1978 (14); strain ITMAP141267, which was isolated from a patient in
the Democratic Republic of Congo in 1960 (5); and strain K03048, which was
isolated from a patient in South Sudan in 2003 (20).
(iii) T. b. brucei. The T. b. brucei strains used include BS221, a derivative of
strain S427 that was isolated in Uganda in 1960; strain AT1KO, a P2 transporter
knockout of the T. b. brucei strain BS221 (23); and strain GVR35, isolated from
a wildebeest in the Serengeti in 1966 (primary isolate S10) (17).
In vitro growth inhibition assays using T. brucei subspecies. The 50% inhib-
itory concentrations (IC50s) were determined by using the Alamar blue assay
(27) and were carried out three times independently and in duplicate. Briefly, the
compounds were tested in minimum essential medium with Earle’s salts, sup-
plemented according to the protocol of Baltz et al. (6) with the following mod-
ifications: 0.2 mM 2-mercaptoethanol, 1 mM Na-pyruvate, 0.5 mM hypoxanthine,
and 15% heat-inactivated horse serum for T. b. rhodesiense and T. b. brucei and
15% human serum plus 5% fetal calf serum for T. b. gambiense. Serial drug
dilutions were prepared in 96-well microtiter plates, and each well was inoculated
with 2,000 bloodstream forms for T. b. rhodesiense or T. b. brucei assay and with
5,000 trypanosomes for T. b. gambiense assay. The drug exposure was at 37°C
under a humidified 5% CO2 atmosphere for 70 h. Ten microliters of the viability
marker Alamar blue (12.5 mg resazurin [Sigma] dissolved in 100 ml phosphate-
buffered saline) was then added to each well, and the plates incubated for an
additional 2 to 6 h until the signal/background fluorescence ratio was about 10
for T. b. rhodesiense and T. b. brucei or about 5 for T. b. gambiense isolates. The
plates were read in a Spectramax Gemini XS microplate fluorescence scanner
(Molecular Devices) using an excitation wavelength of 536 nm and an emission
wavelength of 588 nm. The IC50s were calculated from the sigmoidal inhibition
curves using SoftmaxPro software.
In vivo experiments. Adult female NMRI mice were obtained from RCC,
Ittingen, Switzerland. They weighed between 20 and 25 g at the beginning of the
study and were housed under standard conditions with food pellets and water ad
libitum. All protocols and procedures used in the current study were reviewed
and approved by the local veterinary authorities of the Canton Basel-Stadt,
Switzerland.
STIB900 acute mouse model. The STIB900 acute mouse model mimics the
first stage of the disease. Experiments were performed as previously reported
(31), with minor modifications. Briefly, female NMRI mice were infected intra-
peritoneally (i.p.) with 2  104 STIB900 bloodstream forms. Experimental
groups of four mice were treated i.p. with parent diamidines or orally (per os
[p.o.]) with prodrugs on four consecutive days from day 3 to 6 postinfection. A
control group was infected but remained untreated. The tail blood of all mice was
checked for parasitemia until 60 days after infection. Surviving and aparasitemic
mice at day 60 were considered cured and then euthanized. The day of death of
the animals was recorded (including the cured mice, as 60) to calculate the
mean survival time in days (MSD).
GVR35 mouse CNS model. The GVR35 mouse CNS model mimics the second
stage of the disease. Five female NMRI mice per experimental group were used.
Each mouse was inoculated i.p. with 2  104 bloodstream forms. The treatment
was i.p. for parent compounds and p.o. for prodrugs on five consecutive days
from day 21 to 25 postinfection. Some experimental groups were treated for 10
consecutive days (day 21 to 30 postinfection). A control group was treated on day
21 with a single dose of diminazene aceturate at 40 mg/kg of body weight i.p.,
which is subcurative since it clears the trypanosomes only in the hemolymphatic
system and not in the CNS, leading to a subsequent reappearance of trypano-
somes in the blood (17). Parasitemia was monitored twice in the first week after
treatment followed by once a week until 180 days postinfection. Mice were
considered cured when there was no parasitemia relapse detected in the tail
blood over the 180-day observation period. Surviving mice were euthanized on
day 180, and the day of death of the animals recorded (including the cured mice,
as 180) to calculate the MSD.
RESULTS
In vitro results. The standard drugs melarsoprol, pentami-
dine, and DB75 (furamidine) were tested along with DB820
and DB829 against different T. brucei subspecies isolates in
vitro (Table 1). In vitro data for the prodrugs are not included,
but all were tested against T. b. rhodesiense STIB900wt and it
was confirmed that all prodrugs were inactive (IC50  3,000
ng/ml). All other compounds were highly active, with IC50s of
6.5 ng/ml (14 nM) against the reference strain STIB900wt.
DB829 was less active than DB75 and DB820 or the two
standard drugs. The activity ranking was confirmed repetitively
by several additional in vitro experiments.
All compounds were found to be highly active against three
different T. b. gambiense isolates (IC50  40 ng/ml [85 nM]),
with the activity ranking seen before (DB75  DB820 
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DB829). The sensitivities of the T. b. gambiense isolates were
similar for the drugs used, except for pentamidine. K03048
showed an elevated IC50 of 15.5 ng/ml, which is 14 times higher
than the IC50 for STIB930. The in vitro susceptibilities of T. b.
brucei BS221 were comparable to those of STIB900 for all
compounds tested. AT1KO, the P2 transporter knockout of
BS221, was less susceptible than the wild type. Pentamidine
and melarsoprol demonstrated 4- to 5-fold losses of activity,
while the three diphenylfuran diamidines revealed losses of
activity of 13- to 18-fold (Table 2). The drug susceptibilities of
the melarsoprol- and pentamidine-resistant STIB900 lines to
all tested compounds were strongly reduced, but the highest
cross-resistance was observed between melarsoprol and pentam-
idine. The melarsoprol-resistant trypanosomes showed a high
level of resistance to pentamidine (resistance index, 100), as
high as that of the pentamidine-resistant line. Melarsoprol resis-
tance was high (42-fold) in the melarsoprol-resistant trypano-
somes but lower than their pentamidine resistance and lower than
in the pentamidine-resistant line. Levels of cross-resistance to the
three diphenylfuran diamidines were significantly lower and com-
parable for the pentamidine- and the melarsoprol-resistant lines,
with ratios of activities against STIB900pen/STIB900wt and
STIB900mel/STIB900wt of 10 to 20. All three diphenylfuran dia-
midines were still highly active against both resistant lines, with
IC50s of 15 to 68 ng/ml. Again, DB829 was less potent than DB75.
In vivo STIB900 acute model results. Furamidine and pent-
amidine showed similar efficacies at doses of 20 mg/kg i.p. on
four consecutive days in the in vivo STIB900 acute model, with
three/four and two/four mice cured, respectively (Table 3). The
aza analogs, DB820 and DB829, were both substantially more
potent in this acute model than pentamidine and furamidine,
although their levels of activity in vitro were lower. We ob-
tained good dose responses and comparable efficacies of both
aza compounds with i.p. administration despite the in vitro
activity of DB829 being lower than that of DB820. The dime-
thoxyamidine prodrugs DB844, DB868, and DB289 (Fig. 1)
were all able to cure four/four mice when tested orally in the
STIB900 mouse model (Table 3). DB844 was also tested at a
single dose of 20 mg/kg p.o. and gave three/four cures (data not
presented). Dose responses clearly show that DB844 was more
active than DB868, although their parent drugs had compara-
ble in vivo efficacies.
In vivo GVR35 CNS model results. The prodrug DB289
showed good CNS activity in the in vivo GVR35 CNS model,
with three/five mice cured at a dose of 100 mg/kg p.o. on five
consecutive days (Table 4). Treatment for 10 days at 50 mg/kg
represents an identical total dose but was less effective. DB844
was the first prodrug that cured all mice in the GVR35 mouse
CNS model, at a dose of 100 mg/kg on five consecutive days
administered by the oral route. It was additionally evaluated
with 10-day treatments at different dosages. At 50 mg/kg p.o.
on 10 consecutive days, cures of three/five mice were achieved;
at 25 mg/kg, one/five was cured; and at 10 mg/kg, all mice
relapsed with an MSD comparable to that of diminazene ace-
turate-treated control mice. DB868 had a similar efficacy and
also cured all mice at a dose of 100 mg/kg p.o on five consec-
utive days. The extended 10-day treatment with four different
doses resulted in good dose responses, highlighting the high
CNS activity of DB868. At 100 mg/kg p.o. on 10 consecutive
days, all mice were cured; at 50 mg/kg, four/five mice were
cured; at 25 mg/kg, one/five mice was cured; and at 10 mg/kg,
all mice relapsed, with an MSD similar to that of the control
mice. The data show that although DB844 was more active
than DB868 in the STIB900 acute mouse model, they were
equally active in the mouse CNS model.
The parent compounds DB75, DB820, and DB829 were also
evaluated in the GVR35 mouse CNS model. DB75 did not
cure mice at 20 mg/kg i.p. on five consecutive days, but it did
extend the survival to 92.25 days postinfection, which is a slight
improvement over the survival in the control group treated at
40 mg/kg on one day with diminazene aceturate. DB75 admin-
istered for 10 days at 25 mg/kg i.p. was toxic and killed all mice.
TABLE 1. In vitro antitrypanosomal activity against different trypanosome subspecies and a P2 transporter knockout (AT1KO)
Compound
IC50 (ng/ml) for indicated strain
T. b. rhodesiense T. b. gambiense T. b. brucei
STIB900wt STIB900pent STIB900mel K03048 ITMAP141267 STIB930 BS221 AT1KO
Melarsoprol 1.4 28.2 56.7 3.1 2.7 5.3 3.6 18.7
Pentamidine 1.2 133.6 124.5 15.5 4.2 1.1 0.9 4.1
DB75 1.0 14.3 19.0 4.2 3.1 5.1 1.2 15.8
DB820 2.4 22.5 29.2 8.4 5.7 8.4 2.8 42.9
DB829 6.5 67.9 64.3 39.5 16.2 35.1 6.0 106.4
TABLE 2. In vitro activity indices of different isolates versus that of reference strain STIB900 or BS221
Compound













Melarsoprol 1 20.9 42.0 2.3 2.0 3.9 5.2
Pentamidine 1 113.1 105.4 13.1 3.6 0.9 4.3
DB75 1 14.7 19.5 4.3 3.2 5.3 13.1
DB820 1 9.6 12.4 3.5 2.4 3.5 15.4
DB829 1 10.5 10.0 6.1 2.5 5.4 17.8
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Treatment at 12.5 mg/kg on 10 consecutive days was tolerated
and cured one/four mice. DB820 at 20 mg/kg i.p. on five con-
secutive days did not cure, but it extended the survival of the
mice to 100 days. At an identical daily dose in the extended
10-day treatment, one/five mice was cured without any toxicity
observed. DB829 was the first and is still the only diamidine
that cured single mice at a dose of 20 mg/kg i.p. on five con-
secutive days, and it cured all infected mice when administered
for 10 days at 20 mg/kg i.p. The high CNS activity of DB829
was unexpected and is still unique among diamidines.
In vivo STIB900 acute model results for metabolites. The
monoamidoxime/monomethoxyamidine metabolites (M1s) (Fig.
2) of the dimethoxyamidine prodrugs DB289, DB844, and
DB868 retain prodrug characteristics due to their monoami-
doxime/monomethoxyamidine groups and were therefore ad-
ministered p.o. in the mouse models. All M1s did show oral
activity and cured at least some mice at 50 mg/kg p.o. on four
consecutive days in the STIB900 acute mouse model (Table 5).
DB775, the M1 of DB289, showed the least efficacy. The M1s
of DB844, DB1284 and DB1058, retained excellent activities
and cured all mice at 25 mg/kg p.o. on four consecutive days.
Testing at the very low dose of 5 mg/kg p.o. on four consecutive
days showed that DB1058 was even more active than DB1284.
DB1679, the M1 of DB868, was also highly active and cured all
mice at 25 mg/kg p.o. on four consecutive days. All diami-
doxime metabolites (M2s) were considerably less active in vivo.
None of them gave any cures in the STIB900 acute mouse
model at the tested doses of 75 mg/kg (DB840) or 100 mg/kg
p.o. on four consecutive days (DB290 and DB821).
In vivo GVR35 mouse CNS model results for M1s. The aza
M1s were highly active in the acute mouse model and were
therefore also studied for their CNS activity in the GVR35
mouse CNS model, at 100 mg/kg p.o. on five consecutive days
(Table 6). Only DB775, the M1 of DB289, was not tested due
to inferior STIB900 activity in vivo. Both M1s of DB844,
DB1058 and DB1284, showed high CNS activities. DB1058
cured four/five mice and DB1284 cured all mice at 100 mg/kg
p.o. on five consecutive days. DB1679, the M1 of DB868, also
showed CNS potency (one/five mice cured at 100 mg/kg p.o. on
five consecutive days), but its activity was clearly less than those
of its prodrug DB868 and the M1s of DB844.
DISCUSSION
Treatment of second-stage HAT still depends on only two
drugs, the organoarsenical melarsoprol and eflornithine. Me-
larsoprol is still the first-line drug for HAT in many countries.
This arsenical compound is highly toxic and has severe adverse














Parent (i.p.) DB75 DB820 DB829 Pentamidine
20 3/4 57.75 4/4 60 4/4 60 2/4 57.5
10 ND 4/4 60 4/4 60 ND
5 1/4 46 3/4 54.5 3/4 49.5 2/4 45
2.5 ND 2/4 49 2/4 60 ND
0.5 ND 0/4 29 1/4 31 ND
Prodrug (p.o.) DB289 DB844 DB868
50 4/4 60 ND 4/4 60
25 4/4 60 4/4 60 2/4 42
5 3/4 ND 3/4 50.25 1/4 40.25
2.5 1/4 ND 0/4 19.5 ND
a Dose (mg/kg) was administered on four consecutive days.
b Cure was defined as survival for more than 60 days after infection without showing a parasitemia relapse. MSD (mean survival days) was determined for mice with
and without parasitemia relapse; infected but untreated control mice died between day 6 and day 10 postinfection. ND, not determined.
FIG. 1. Dimethoxyamidine prodrugs and their active parent diamidines.
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effects which lead to fatalities in 5% of the patients treated
(18). Additionally, there are alarming reports of treatment
failures of up to 30% (7). Recent reports also indicate emerg-
ing resistance against eflornithine, the only alternative drug for
second-stage HAT, with treatment failure rates already up to
16% (4). Nifurtimox, a drug against Chagas disease, is not very
active against African trypanosomes as monotherapy, but in
combination with melarsoprol and, especially, eflornithine,
very promising results could be seen in clinical trials (9, 12, 26).
The combination therapy may not work for isolates with some
degree of resistance to melarsoprol or eflornithine. In a worst-
case scenario, there could be no effective drug available for
second-stage HAT in less than a decade. New safe and effec-
tive drugs are urgently needed for both disease stages to treat
thousands of patients.
So far, no resistance has been reported in the field for
pentamidine, although this drug has been in use for first-stage
T. b. gambiense HAT for decades (23). This makes pentami-
dine an attractive molecule for analog-based drug discovery.
To overcome the low oral bioavailability and the lack of CNS
penetration, prodrugs were designed for this study.
In comparing the IC50s of the aromatic diamidines DB75,
DB820, and DB829, it became obvious that DB829 had higher
IC50s than DB75 and DB820 against all trypanosome strains








Resulta for indicated compound
No. of mice





Parent (i.p.) DB75 DB820 DB829
20/5 0/4b 92.25 0/4b 102.5 1/4b 132.3
20/10 Toxicd NA 1/5 128.2 4/4b 180
10/10 1/4c 112c ND 0/5 95.6
Prodrug (p.o.) DB289 DB844 DB868
100/5 3/5 167.8 5/5 180 5/5 180
50/5 0/5 153.6 1/5 176.6 ND
25/5 0/5 75.4 0/5 117.6 0/4b 95.8
100/10 ND ND 5/5 180
50/10 1/5 172.2 3/5 180 4/5 153.4
25/10 0/5 146.6 1/5 149.6 1/5 132.4
10/10 ND 0/5 75.25 0/5 70.0






a Cure was defined as survival for more than 180 days after infection without showing a parasitemia relapse. MSD (mean survival days) was determined for mice with
and without parasitemia relapse. ND, not determined. NA, not applicable.
b One mouse died during or directly after treatment (day 21 to day 28).
c DB75 was tested at 12.5 mg/kg i.p. for 10 consecutive days and cured one/four mice.
d DB75 tested at 25 mg/kg i.p. for 10 consecutive days was toxic.
e Melarsoprol.
f Diminazene aceturate. MSD of the diminazene aceturate-treated control group was 47 to 83 in different experiments.
FIG. 2. Monoamidoxime/monomethoxyamidine metabolites (M1s) and diamidoxime metabolites (M2s).
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tested. All three diamidines were less active against the T. b.
gambiense isolates (3- to 6-fold), the P2-transporter knockout
of BS221 (15-fold), and the laboratory-induced drug-resis-
tant lines of STIB900 (10- to 20-fold) (Table 2). The T. b.
gambiense strain K03048 from South Sudan revealed a differ-
ent sensitivity to pentamidine than the old drug-sensitive T. b.
gambiense strain STIB930. Pentamidine resistance in the field
has not been demonstrated; however, a reduced pentamidine
susceptibility of K03048 was observed previously with a differ-
ent in vitro method (hypoxanthine incorporation assay over
48 h) (20). K03048 was isolated from a patient in Ibba, Sudan,
an area with high melarsoprol failure rates. This isolate, how-
ever, is melarsoprol sensitive in vitro and in the mouse model
(20). The drug response of K03048 to the diamidines was
comparable to those of the other two T. b. gambiense isolates.
The two STIB900 lines selected for resistance to melarsoprol
and pentamidine had 10- to 20-fold-increased IC50s against the
three diamidines. Molecular analysis revealed that the try-
panosomes selected for melarsoprol resistance have lost the
TbAT1 gene that codes for the P2 transporter (23), while in the
pentamidine-selected trypanosomes, the TbAT1 gene was still
present (8). Whether its P2 transporter is functionally ex-
pressed has not yet been investigated. Comparable resistance
indices of the diphenylfuran diamidines for melarsoprol-resis-
tant/wild type and AT1KO/wild type strains indicate that the
moderate cross-resistance can probably be attributed to the
loss of the P2 transporter only. The higher pentamidine resis-
tance of the two resistant STIB900 lines indicates that there
are additional alterations involved which cause loss of pentam-
idine sensitivity but not loss of sensitivity against the diphe-
nylfuran diamidines. The P2 transporter has been identified as
the primary uptake route for DB75 (19), but at least one other
transporter participates in its uptake as well. In contrast, me-
larsoprol and pentamidine show only minor differences in ac-
tivities in AT1KO and its wild type (at least two transporters
involved in drug uptake). Bridges at al. have shown that the
high-affinity pentamidine transporter (HAPT1) was absent
from their high-level pentamidine-resistant and melarsoprol-
resistant trypanosomes (11). If the high-level resistance of the
melarsoprol- and pentamidine-selected STIB900 lines is simi-
larly caused by a concomitant loss of TbAT1 and HAPT1, then
the comparable loss of sensitivity of AT1KO indicates that
HAPT1 is not involved or has only a minor impact on the
uptake of furamidine and its aza analogs. The second major
route of uptake has not yet been identified. Selective drug
uptake can develop resistance, but on the other hand, it also
facilitates selective uptake and drug accumulation by the par-
asite.
TABLE 5. In vivo activity of intermediates in the STIB900 acute mouse model
Prodrug Dosea








100 ND 0/4 50
50 1/4 56 ND
15 0/4 30.25 ND
DB844 DB1284 DB1058 DB821
100 ND 4/4 60 0/4 54
25 4/4 60 4/4 60 ND
5 1/4 39.5 3/4 52.75 ND
DB868 DB1679 DB840
75 ND 0/4 18
25 4/4 60 ND
5 0/3c 29.7 ND
a Dose (mg/kg) was administered p.o. on four consecutive days.
b Cure was defined as survival for more than 60 days after infection without showing a parasitemia relapse. MSD (mean survival days) was determined for mice with
and without parasitemia relapse; infected but untreated control mice died between day 6 and 10 postinfection. ND, not determined.
c One mouse died due to p.o. application, with no toxicity observed.
TABLE 6. In vivo activities of M1s versus those of dimethoxyamidine prodrugs in the GVR35 CNS model
Dosea
Resultb for indicated compound:





















100 5/5 180 4/5 180 5/5 180 5/5 180 1/5 140.4
75 3/4, 1/5 180, 172 1/5 166 2/5 164.8 ND ND
50 1/5 176.6 ND 1/5 157.2 ND ND
a Dose (mg/kg) was administered p.o. on five consecutive days.
b Cure was defined as survival for more than 180 days after infection without showing a parasitemia relapse. MSD (mean survival days) was determined for mice with
and without parasitemia relapse. ND, not determined.
c DB844 has been tested twice at 75 mg/kg on five consecutive days; the 3/4 result is from a previous experiment, and the 1/5 result is from an experiment that included
both M1s, DB1058 and DB1284.
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DB820 and DB829 show in vivo activities superior to those
of DB75 and pentamidine in both the acute and the mouse
CNS model. Both aza parent compounds demonstrated com-
parable efficacies with no signs of overt toxicity after i.p. ad-
ministration in the STIB900 acute mouse model. Both aza
prodrugs, DB844 and DB868, were almost as efficacious as
DB289 in the acute mouse model and were well tolerated at all
doses tested. DB844 was more potent than DB868, although
the parent compounds revealed similar efficacies. According to
their efficacies in the acute model, both prodrugs could have
the potential to serve as backup drugs to replace DB289 as the
next oral drug to treat first-stage disease. However, the main
focus and urgency is on finding a new treatment for second-
stage HAT and an option for treatment after treatment fail-
ures with melarsoprol or eflornithine. The ideal solution would
be one drug with the target product profile of a first-stage drug
that could be used for both stages, thus rendering the painful
lumbar puncture so far required for staging unnecessary.
DB868 was equally as potent as DB844 in the GVR35 mouse
CNS model, despite its lower level of activity in the acute
model. Both prodrugs have potential as oral drugs for second-
stage sleeping sickness, according to their high CNS activity in
the mouse model. However, safety studies of DB844 in the
vervet monkey model for HAT demonstrated dose-dependent
toxicity, especially, dose-limiting gastrointestinal toxicity, not
previously observed with DB289 (John Thuita, personal com-
munication). At 10 and 20 mg/kg p.o. for 10 days, it caused
tissue damage in the gastrointestinal tract and liver, whereas at
5 mg/kg for 10 days, the clinical signs and hematological pa-
rameters were normal. But at 5 mg/kg, only three/eight vervet
monkeys with CNS infection were cured (John Thuita, per-
sonal communication). The observed toxicity stopped further
investigations of DB844. Recent toxicity studies of vervet mon-
keys have been completed for DB868. No signs of overt toxicity
were observed in animals dosed for 10 days at 10 mg/kg or even
30 mg/kg p.o. (John Thuita, personal communication). DB868
does remain a promising preclinical candidate as it is substan-
tially better tolerated than DB844 and DB289.
The high CNS activity of DB829 after i.p. administration was
a surprise. This is the first parent diamidine that could cure all
mice tested in the mouse CNS model. Passive diffusion across
the BBB to reach sufficient concentrations in the CNS is un-
likely for such a positively charged molecule. The transport is
more likely to be mediated by specific transporters located in
the BBB. Parenteral administration is an acceptable route of
administration for second-stage HAT considering the fatal
outcome without effective treatment.
The M1s of DB844 and DB868 were similarly active when
administered orally in the acute mouse model and were almost
as potent as their prodrugs. They could serve as orally active
prodrug alternatives. DB1284 (metabolite of DB844) was
slightly less active than the other metabolite, DB1058. The
amidoxime metabolites of DB844 and DB868 lost the oral
activity of the prodrugs. Previously, diamidoxime prodrugs
have been shown to be less potent in the STIB900 acute model
in several but not all cases (2, 16).
The M1s of DB844 and DB868 were also active in the mouse
CNS model. Interestingly, DB1284, which was less active in the
acute mouse model, did show a slightly higher efficacy in the
mouse CNS model than DB1058 when tested at 75 mg/kg p.o.
on five consecutive days. The bioactivation of the M1 to its
active principle is abbreviated and therefore simplified in com-
parison to that of the dimethoxyamidine prodrug. It is conceiv-
able to replace the prodrug with the M1 if other selection
criteria, such as toxicity, simple pharmacokinetics, and cost of
goods, are superior. DB1679, the M1 of DB868, is less CNS
potent than DB868 and is therefore currently not considered
an alternative candidate.
DB868, DB1058, and DB1284 are similarly CNS active in
GVR35-infected mice and are candidates for an oral treatment
for second-stage HAT. Their parent drugs showed comparable
in vitro drug resistance and subspecies profiles. So far, DB868
has been the favored prodrug since its parent, DB829, is CNS
active itself and its metabolism is simpler than that of its
asymmetric analog (3). However, in several clinical trials with
DB289, a highly variable pharmacokinetic profile was ob-
served; it can be speculated that this may be due to the com-
plicated metabolic prodrug activation (Christian Burri, per-
sonal communication). As parenterally administered DB829
penetrates the BBB, the pharmacokinetics will be much sim-
plified compared to those of a prodrug treatment and predic-
tions of optimized treatment regimes more reliable and there-
fore safer. Parenteral treatment for second-stage disease is
acceptable, and DB829 may have potential to become the next
new treatment option for second-stage HAT. To determine if
it is indeed a leading preclinical candidate drug, extensive
toxicity and efficacy studies for parenteral DB829 (CPD-0801)
must be performed with vervet monkeys.
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